CA2501089A1 - Composes antitumoraux - Google Patents

Composes antitumoraux Download PDF

Info

Publication number
CA2501089A1
CA2501089A1 CA002501089A CA2501089A CA2501089A1 CA 2501089 A1 CA2501089 A1 CA 2501089A1 CA 002501089 A CA002501089 A CA 002501089A CA 2501089 A CA2501089 A CA 2501089A CA 2501089 A1 CA2501089 A1 CA 2501089A1
Authority
CA
Canada
Prior art keywords
cancer
compound
pharmaceutically acceptable
affected
psoriasis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002501089A
Other languages
English (en)
Other versions
CA2501089C (fr
Inventor
Glynn Thomas Faircloth
Mariano Elices
Halina Sasak
Pablo Manuel Aviles Marin
Maria Del Carmen Cuevas Marchante
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmamar SA
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2002/004735 external-priority patent/WO2003033012A1/fr
Priority claimed from GBGB0304367.6A external-priority patent/GB0304367D0/en
Priority claimed from GB0314725A external-priority patent/GB0314725D0/en
Application filed by Individual filed Critical Individual
Priority claimed from PCT/US2003/033207 external-priority patent/WO2004035613A2/fr
Publication of CA2501089A1 publication Critical patent/CA2501089A1/fr
Application granted granted Critical
Publication of CA2501089C publication Critical patent/CA2501089C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des composés antitumoraux kahalalide, notamment des analogues de kahalalide F, utiles en tant qu'agents antitumoraux, antiviraux, antifongiques et dans le traitement du psoriasis.
CA2501089A 2002-10-18 2003-10-20 Composes antitumoraux Expired - Fee Related CA2501089C (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
PCT/GB2002/004735 WO2003033012A1 (fr) 2001-10-19 2002-10-18 Composes a base de kahalalide utilisables en therapie anticancereuse
GBPCT/GB02/004735 2002-10-18
GBGB0304367.6A GB0304367D0 (en) 2003-02-26 2003-02-26 Methods for treating psoriasis
GB0304367.6 2003-02-26
GB0314725A GB0314725D0 (en) 2003-06-24 2003-06-24 New antitumoral compounds
GB0314725.3 2003-06-24
PCT/US2003/033207 WO2004035613A2 (fr) 2002-10-18 2003-10-20 Composes antitumoraux

Publications (2)

Publication Number Publication Date
CA2501089A1 true CA2501089A1 (fr) 2004-04-29
CA2501089C CA2501089C (fr) 2012-07-17

Family

ID=35276268

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2501089A Expired - Fee Related CA2501089C (fr) 2002-10-18 2003-10-20 Composes antitumoraux

Country Status (13)

Country Link
KR (2) KR101149095B1 (fr)
AT (1) ATE490975T1 (fr)
AU (1) AU2003285911B2 (fr)
CA (1) CA2501089C (fr)
CY (1) CY1111319T1 (fr)
DE (1) DE60335292D1 (fr)
DK (1) DK1572726T3 (fr)
ES (1) ES2357644T3 (fr)
IL (1) IL167724A (fr)
NO (1) NO333448B1 (fr)
PL (1) PL209129B1 (fr)
PT (1) PT1572726E (fr)
SI (1) SI1572726T1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0321066D0 (en) * 2003-09-09 2003-10-08 Pharma Mar Sau New antitumoral compounds
GB0408958D0 (en) * 2004-04-22 2004-05-26 Pharma Mar Sa Convergent synthesis for kahalalide compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9302046D0 (en) * 1993-02-03 1993-03-24 Pharma Mar Sa Antiumoral compound-v
NZ525243A (en) * 2000-10-31 2005-01-28 Pharma Mar S A lyophilised formulation comprising kahalalide F, a peptide isolated from a herbivorous marine species of mollusc, Elysia rufescens, to treat cancer
EP1435990A1 (fr) * 2001-10-19 2004-07-14 Pharma Mar, S.A. Composes a base de kahalalide utilisables en therapie anticancereuse

Also Published As

Publication number Publication date
KR20050070056A (ko) 2005-07-05
CY1111319T1 (el) 2015-08-05
ES2357644T3 (es) 2011-04-28
DK1572726T3 (da) 2011-03-28
PL377056A1 (pl) 2006-01-23
CA2501089C (fr) 2012-07-17
PT1572726E (pt) 2011-02-14
PL209129B1 (pl) 2011-07-29
ATE490975T1 (de) 2010-12-15
KR20110114690A (ko) 2011-10-19
NO20052379D0 (no) 2005-05-13
AU2003285911A1 (en) 2004-05-04
NO333448B1 (no) 2013-06-10
KR101149095B1 (ko) 2012-05-30
NO20052379L (no) 2005-07-15
IL167724A (en) 2012-01-31
DE60335292D1 (de) 2011-01-20
HK1082261A1 (en) 2006-06-02
AU2003285911B2 (en) 2009-11-19
SI1572726T1 (sl) 2011-04-29

Similar Documents

Publication Publication Date Title
ES2269769T3 (es) Terapia de combinacion ee comprende zd6474 y un taxano.
YU23202A (sh) Lekovi za tretman malignih tumora
ATE358668T1 (de) Drogen zur behandlung maligner tumoren
RU2006122853A (ru) Производные диарилмочевины для лечения заболеваний, зависимых от протеинкиназы
JP2008535902A5 (fr)
UA83182C2 (en) Compounds effecting glucokinase
MX2007002398A (es) Nuevas composiciones farmaceuticas para el tratamiento de cancer.
IL147271A (en) Isolated peptide ligands that bind to her2
RU2011139107A (ru) Специфические соединения диарилгидантоина и диарилтиогидантоина
WO2003030908A3 (fr) Methode de traitement du cancer thyroidien
TNSN07294A1 (en) Treatment of metastasized tumors
AU2002357191A1 (en) Derivatives of isoindigo, indigo and indirubin and use in treating cancer
PL342614A1 (en) Anticarcinogenic drugs
WO2003017939A3 (fr) Composes de piperazinone utilises comme agents antitumoraux et anticancereux et procedes de traitement
MX2025009374A (es) Compuesto que contiene trifluorometilsulfonilo
IL150817A0 (en) Pyrrole-type compounds, compositions, and methods for treating cancer or viral diseases
JP2006517195A5 (fr)
RU2000128037A (ru) Списулозиновые соединения, обладающие противоопухолевой активностью
MX2007006043A (es) Metodo de tratamiento de cancer.
YU77002A (sh) Postupak i preparat za tretiranje kancera putem davanja hemoterapeutskog agensa koji indukuje apoptozis
AU2003241024A1 (en) Methods and compositions for radioimmunotherapy of brain and cns tumors
RU2005115102A (ru) Новые противоопухолевые соединения
CA2501089A1 (fr) Composes antitumoraux
EP1496979A4 (fr) Complexes de vecteur adenoviral-protamine et procedes d'utilisation
BR0213486A (pt) Combinações que compreendem um inibidor seletivo de ciclooxigenase-2

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20171020